Table 2 Concentration of plasma edoxaban (ng/ml) during the study
Time point | All patients (n = 16) | Cancer type | Edoxaban dosage | ||
|---|---|---|---|---|---|
Ovarian (n = 12) | Uterus corpus (n = 4) | 60 mg (n = 3) | 30 mg (n = 13) | ||
1 | 17.7 ± 10.9 | 14.9 ± 6.2 | 26.8 ± 16.6 | 15.6 ± 6.0 | 26.3 ± 22.4 |
2 | 216.6 ± 119.9 | 211.8 ± 93.2 | 229.9 ± 194.4 | 188.8 ± 78.2 | 330.4 ± 206.6 |
3 | 20.0 ± 15.6 | 15.2 ± 7.4 | 33.1 ± 25.2 | 16.0 ± 7.2 | 36.1 ± 30.4 |
4 | 257.1 ± 123.6 | 237.4 ± 82.5 | 311.3 ± 208.0 | 207.9 ± 68.8 | 453.7 ± 92.0 |
5 | 14.3 ± 7.8 | 12.8 ± 4.3 | 16.8 ± 12.7 | 11.9 ± 4.4 | 21.5 ± 13.9 |
6 | 222.4 ± 119.6 | 156.4 ± 53.4 | 332.3 ± 123.8 | 164.4 ± 51.6 | 396.5 ± 77.1 |